Clinical Trials Logo

Larynx Squamous Cell Carcinoma clinical trials

View clinical trials related to Larynx Squamous Cell Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05712356 Recruiting - Clinical trials for Head and Neck Cancer

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

BOLSTER
Start date: August 24, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in patients with advanced head and neck squamous cell carcinoma and cholangiocarcinoma. The main questions it aims to answer are: - is the new drug plus standard treatment safe and tolerable - is the new drug plus standard treatment more effective than standard treatment

NCT ID: NCT04858269 Recruiting - Clinical trials for Oral Cavity Squamous Cell Carcinoma

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

Start date: May 27, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this research is to see what effects the treatment regimen chemotherapy (carboplatin and paclitaxel) plus immunotherapy (pembrolizumab), has on patients who have been diagnosed with head/neck squamous cell carcinoma and are unable to take the drug 5-fluorouracil

NCT ID: NCT04445064 Recruiting - Clinical trials for Oral Cavity Squamous Cell Carcinoma

Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.

HN1901
Start date: August 14, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this project is to realize a randomized open-label study (EudraCT number: 2020-000120-19) to evaluate the safety and the anti-tumor activity of peptide(s)-based immunotherapy in an umbrella window pre-operative opportunity phase II study in patients with squamous cell carcinoma of the head and neck.

NCT ID: NCT03381183 Active, not recruiting - Clinical trials for Squamous Cell Carcinoma

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

Start date: August 21, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to see if the IRX-2 regimen and Durvalumab, will have a tolerable safety profile and will increase the intratumoral immune profile compared with the pretreatment tumors.